Galderma will present new data on Relfydess (RelabotulinumtoxinA) – the first and only ready-to-use liquid neuromodulator created using PEARL™ Technology, which has now launched in multiple countries in Europe – including results from the phase IIIb RELAX trial, reinforcing its long-term efficacy and high patient satisfaction, as seen in the READY clinical trial program1-7
Galderma will present new data from across its portfolio, including findings from the RELAX and EXPRESSION studies on Relfydess® (RelabotulinumtoxinA) highlighting its rapid onset of action as early as day one and sustained high patient satisfaction beyond six months1,2
Lausanne, Switzerland – June 1, 2018 – Galderma today released the findings of a global survey highlighting the need for dermatologists and doctors to proactively open a dialogue with patients about the true burden of rosacea and ways in which they can work together to achieve ‘clear’ (IGA 0) skin*.
Atopic dermatitis is a common, chronic, and flaring inflammatory skin disease characterized by persistent itch and recurrent skin lesions, and affects approximately up to 40 million people in the European Union (EU)1-4
Prurigo nodularis is a serious skin disease characterized by chronic itch, skin nodules covering large body areas, and poor sleep quality, which is es
